A detailed history of Citigroup Inc transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 20,192 shares of ITOS stock, worth $145,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,192
Previous 11,695 72.65%
Holding current value
$145,786
Previous $173,000 19.08%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.09 - $17.97 $85,734 - $152,691
8,497 Added 72.65%
20,192 $206,000
Q2 2024

Aug 12, 2024

SELL
$10.33 - $18.09 $2.94 Million - $5.14 Million
-284,289 Reduced 96.05%
11,695 $173,000
Q1 2024

May 10, 2024

SELL
$9.89 - $13.64 $482,810 - $665,877
-48,818 Reduced 14.16%
295,984 $4.04 Million
Q4 2023

Feb 09, 2024

BUY
$8.57 - $11.06 $2.22 Million - $2.86 Million
258,468 Added 299.38%
344,802 $3.78 Million
Q3 2023

Nov 09, 2023

SELL
$10.95 - $14.6 $1.62 Million - $2.17 Million
-148,333 Reduced 63.21%
86,334 $945,000
Q2 2023

Aug 10, 2023

SELL
$12.93 - $18.05 $701,038 - $978,634
-54,218 Reduced 18.77%
234,667 $3.11 Million
Q1 2023

May 11, 2023

BUY
$13.02 - $22.62 $710,748 - $1.23 Million
54,589 Added 23.3%
288,885 $3.93 Million
Q4 2022

Feb 09, 2023

SELL
$17.77 - $21.6 $1.07 Million - $1.3 Million
-59,957 Reduced 20.38%
234,296 $4.58 Million
Q3 2022

Nov 10, 2022

BUY
$18.6 - $27.25 $3.14 Million - $4.59 Million
168,551 Added 134.09%
294,253 $5.61 Million
Q2 2022

Aug 10, 2022

BUY
$16.57 - $35.1 $1.55 Million - $3.28 Million
93,349 Added 288.53%
125,702 $2.59 Million
Q1 2022

May 12, 2022

SELL
$31.92 - $47.45 $5.62 Million - $8.36 Million
-176,147 Reduced 84.48%
32,353 $1.04 Million
Q4 2021

Feb 10, 2022

SELL
$26.23 - $47.86 $5.38 Million - $9.81 Million
-204,972 Reduced 49.57%
208,500 $9.71 Million
Q3 2021

Nov 10, 2021

BUY
$23.91 - $29.58 $9.89 Million - $12.2 Million
413,472 New
413,472 $11.2 Million

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $257M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.